Search for companies, drugs, and catalysts
Phase 2
Development Phase
0
Upcoming Catalysts
Historical Events
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Neurotrophic Keratopathy
Clinical Trial
Last updated: 12/4/2025
OYST
Oyster Point Pharma, Inc.
